{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:12:05Z","timestamp":1761743525645},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Head Neck Oncol"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>To report the outcomes of patients with locoregionally advanced and high- risk salivary gland malignancies treated with surgery followed by adjuvant chemoradiotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>From 09\/1991 - 06\/2007, 24 high-risk salivary gland cancer patients were treated with surgery, followed by adjuvant chemoradiotherapy for high-risk pathologic features including, perineural involvement, nodal involvement, positive margins, or T3\/T4 tumors. Chemoradiotherapy was delivered for 4-6 alternating week cycles: the most common regimen, TFHX, consisted of 5 days paclitaxel (100 mg\/m<jats:sup>2<\/jats:sup> on d1), infusional 5-fluorouracil (600 mg\/m<jats:sup>2<\/jats:sup>\/d \u00d7 5d), hydroxyurea (500 mg PO BID), and 1.5 Gy twice daily irradiation followed by a 9-day break without treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Median follow-up was 42 months. The parotid gland was more frequently involved (n = 17) than minor (n = 4) or submandibular (n = 3) glands. The median radiation dose was 65 Gy (range 55-68 Gy). Acute treatment related toxicity included 46% grade 3 mucositis and 33% grade 3 hematologic toxicity. Six patients required feeding tubes during treatment. One patient progressed locally, 8 patients progressed distantly, and none progressed regionally. Five-year locoregional progression free survival was 96%. The 3 and 5 year overall survival was 79% and 59%, respectively. Long-term complications included persistent xerostomia (n = 5), esophageal stricture requiring dilatation (n = 1), and tempromandibular joint syndrome (n = 1).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Surgical resection followed by adjuvant chemoradiotherapy results in promising locoregional control for high-risk salivary malignancy patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1758-3284-3-31","type":"journal-article","created":{"date-parts":[[2011,7,27]],"date-time":"2011-07-27T06:18:29Z","timestamp":1311747509000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies"],"prefix":"10.1186","volume":"3","author":[{"given":"Aaron W","family":"Pederson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph K","family":"Salama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J","family":"Haraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Ellen","family":"Witt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin M","family":"Stenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Portugal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanguy","family":"Seiwert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria M","family":"Villaflor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezra EW","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Everett E","family":"Vokes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A","family":"Blair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,7,26]]},"reference":[{"key":"215_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1001\/archotol.1990.01870030054008","volume":"116","author":"JG Armstrong","year":"1990","unstructured":"Armstrong JG, Harrison LB, Spiro RH, Fass DE, Strong EW, Fuks ZY: Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy. Arch Otolaryngol Head Neck Surg. 1990, 116: 290-293.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"215_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/0360-3016(93)90233-L","volume":"27","author":"GE Laramore","year":"1993","unstructured":"Laramore GE, Krall JM, Griffin TW, et al: Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Int J Radiat Oncol Biol Phys. 1993, 27: 235-240.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"215_CR3","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijrobp.2006.07.1380","volume":"67","author":"AM Chen","year":"2007","unstructured":"Chen AM, Garcia J, Bucci MK, Quivey JM, Eisele DW: The role of postoperative radiation therapy in carcinoma ex pleomorphic adenoma of the parotid gland. Int J Radiat Oncol Biol Phys. 2007, 67: 138-143. 10.1016\/j.ijrobp.2006.07.1380.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"215_CR4","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.ijrobp.2006.10.043","volume":"67","author":"AM Chen","year":"2007","unstructured":"Chen AM, Granchi PJ, Garcia J, Bucci MK, Fu KK, Eisele DW: Local-regional recurrence after surgery without postoperative irradiation for carcinomas of the major salivary glands: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 2007, 67: 982-987. 10.1016\/j.ijrobp.2006.10.043.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"215_CR5","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1002\/1097-0142(197712)40:6<2882::AID-CNCR2820400618>3.0.CO;2-I","volume":"40","author":"KK Fu","year":"1977","unstructured":"Fu KK, Leibel SA, Levine ML, Friedlander LM, Boles R, Phillips TL: Carcinoma of the major and minor salivary glands: analysis of treatment results and sites and causes of failures. Cancer. 1977, 40: 2882-2890. 10.1002\/1097-0142(197712)40:6<2882::AID-CNCR2820400618>3.0.CO;2-I.","journal-title":"Cancer"},{"key":"215_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/jso.2930450112","volume":"45","author":"LB Harrison","year":"1990","unstructured":"Harrison LB, Armstrong JG, Spiro RH, Fass DE, Strong EW: Postoperative radiation therapy for major salivary gland malignancies. J Surg Oncol. 1990, 45: 52-55. 10.1002\/jso.2930450112.","journal-title":"J Surg Oncol"},{"key":"215_CR7","first-page":"671","volume":"12","author":"RH Spiro","year":"1998","unstructured":"Spiro RH: Management of malignant tumors of the salivary glands. Oncology (Williston Park). 1998, 12: 671-680. discussion 683","journal-title":"Oncology (Williston Park)"},{"key":"215_CR8","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1016\/j.ijrobp.2007.04.079","volume":"69","author":"CH Terhaard","year":"2007","unstructured":"Terhaard CH: Postoperative and primary radiotherapy for salivary gland carcinomas: indications, techniques, and results. Int J Radiat Oncol Biol Phys. 2007, 69: S52-55.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"215_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijrobp.2004.03.018","volume":"61","author":"CH Terhaard","year":"2005","unstructured":"Terhaard CH, Lubsen H, Rasch CR, et al: The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys. 2005, 61: 103-111. 10.1016\/j.ijrobp.2004.03.018.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"215_CR10","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/1097-0142(19871215)60:12<2869::AID-CNCR2820601203>3.0.CO;2-Y","volume":"60","author":"AI Dreyfuss","year":"1987","unstructured":"Dreyfuss AI, Clark JR, Fallon BG, Posner MR, Norris CM, Miller D: Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer. 1987, 60: 2869-2872. 10.1002\/1097-0142(19871215)60:12<2869::AID-CNCR2820601203>3.0.CO;2-Y.","journal-title":"Cancer"},{"key":"215_CR11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/019459988609500206","volume":"95","author":"MJ Kaplan","year":"1986","unstructured":"Kaplan MJ, Johns ME, Cantrell RW: Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg. 1986, 95: 165-170.","journal-title":"Otolaryngol Head Neck Surg"},{"key":"215_CR12","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/oxfordjournals.annonc.a010684","volume":"7","author":"L Licitra","year":"1996","unstructured":"Licitra L, Cavina R, Grandi C, et al: Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol. 1996, 7: 640-642.","journal-title":"Ann Oncol"},{"key":"215_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.oraloncology.2004.03.002","volume":"41","author":"LD Locati","year":"2005","unstructured":"Locati LD, Rinaldi G, Bossi P, et al: Herceptin plus chemotherapy in relapsed and\/or metastatic salivary gland cancer. Oral Oncol. 2005, 41: 97-98.","journal-title":"Oral Oncol"},{"key":"215_CR14","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/S0278-2391(96)90119-6","volume":"54","author":"C Chou","year":"1996","unstructured":"Chou C, Zhu G, Luo M, Xue G: Carcinoma of the minor salivary glands: results of surgery and combined therapy. J Oral Maxillofac Surg. 1996, 54: 448-453. 10.1016\/S0278-2391(96)90119-6.","journal-title":"J Oral Maxillofac Surg"},{"key":"215_CR15","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1097\/00005537-200108000-00021","volume":"111","author":"E Hocwald","year":"2001","unstructured":"Hocwald E, Korkmaz H, Yoo GH, et al: Prognostic factors in major salivary gland cancer. Laryngoscope. 2001, 111: 1434-1439. 10.1097\/00005537-200108000-00021.","journal-title":"Laryngoscope"},{"key":"215_CR16","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/1097-0142(19870301)59:5<887::AID-CNCR2820590505>3.0.CO;2-8","volume":"59","author":"PL Triozzi","year":"1987","unstructured":"Triozzi PL, Brantley A, Fisher S, Cole TB, Crocker I, Huang AT: 5-Fluorouracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck. Cancer. 1987, 59: 887-890. 10.1002\/1097-0142(19870301)59:5<887::AID-CNCR2820590505>3.0.CO;2-8.","journal-title":"Cancer"},{"key":"215_CR17","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1080\/00016480600818070","volume":"126","author":"H Katori","year":"2006","unstructured":"Katori H, Tsukuda M: Concurrent chemoradiotherapy with cyclophosphamide, pirarubicin, and cisplatin for patients with locally advanced salivary gland carcinoma. Acta Otolaryngol. 2006, 126: 1309-1314. 10.1080\/00016480600818070.","journal-title":"Acta Otolaryngol"},{"key":"215_CR18","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10147-006-0587-0","volume":"11","author":"S Maruya","year":"2006","unstructured":"Maruya S, Namba A, Matsubara A, et al: Salivary gland carcinoma treated with concomitant chemoradiation with intraarterial cisplatin and docetaxel. Int J Clin Oncol. 2006, 11: 403-406. 10.1007\/s10147-006-0587-0.","journal-title":"Int J Clin Oncol"},{"key":"215_CR19","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1634\/theoncologist.8-4-350","volume":"8","author":"A Argiris","year":"2003","unstructured":"Argiris A, Haraf DJ, Kies MS, Vokes EE: Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. Oncologist. 2003, 8: 350-360. 10.1634\/theoncologist.8-4-350.","journal-title":"Oncologist"},{"key":"215_CR20","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"ELMP Kaplan","year":"1958","unstructured":"Kaplan ELMP: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958, 53: 547-581.","journal-title":"J Am Stat Assoc"},{"key":"215_CR21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/ncponc0750","volume":"4","author":"TY Seiwert","year":"2007","unstructured":"Seiwert TY, Salama JK, Vokes EE: The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol. 2007, 4: 156-171. 10.1038\/ncponc0750.","journal-title":"Nat Clin Pract Oncol"},{"key":"215_CR22","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1200\/JCO.2007.12.2697","volume":"25","author":"JK Salama","year":"2007","unstructured":"Salama JK, Seiwert TY, Vokes EE: Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol. 2007, 25: 4118-4126. 10.1200\/JCO.2007.12.2697.","journal-title":"J Clin Oncol"},{"key":"215_CR23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/030089160108700103","volume":"87","author":"M Airoldi","year":"2001","unstructured":"Airoldi M, Gabriele AM, Gabriele P, et al: Concomitant chemoradiotherapy followed by adjuvant chemotherapy in parotid gland undifferentiated carcinoma. Tumori. 2001, 87: 14-17.","journal-title":"Tumori"},{"key":"215_CR24","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.ijrobp.2006.06.050","volume":"66","author":"AM Chen","year":"2006","unstructured":"Chen AM, Bucci MK, Quivey JM, Garcia J, Eisele DW, Fu KK: Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas. Int J Radiat Oncol Biol Phys. 2006, 66: 1044-1050. 10.1016\/j.ijrobp.2006.06.050.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"215_CR25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/978-3-540-47072-4_27","volume-title":"Salivary Gland Disorders","author":"GE Laramore","year":"2007","unstructured":"Laramore GE: Role of Radiotherapy in the Treatment of Tumors of the Salivary Glands. Salivary Gland Disorders. Edited by: Myers ENF, R L. 2007, Springer, 463-475."},{"key":"215_CR26","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/archotol.129.9.944","volume":"129","author":"JG Douglas","year":"2003","unstructured":"Douglas JG, Koh WJ, Austin-Seymour M, Laramore GE: Treatment of salivary gland neoplasms with fast neutron radiotherapy. Arch Otolaryngol Head Neck Surg. 2003, 129: 944-948. 10.1001\/archotol.129.9.944.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"215_CR27","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1053\/j.seminoncol.2008.03.009","volume":"35","author":"SG Surakanti","year":"2008","unstructured":"Surakanti SG, Agulnik M: Salivary gland malignancies: the role for chemotherapy and molecular targeted agents. Semin Oncol. 2008, 35: 309-319. 10.1053\/j.seminoncol.2008.03.009.","journal-title":"Semin Oncol"},{"key":"215_CR28","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.2007.11.8612","volume":"25","author":"M Agulnik","year":"2007","unstructured":"Agulnik M, Cohen EW, Cohen RB, et al: Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and\/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol. 2007, 25: 3978-3984. 10.1200\/JCO.2007.11.8612.","journal-title":"J Clin Oncol"},{"key":"215_CR29","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/S1368-8375(03)00097-6","volume":"39","author":"R Haddad","year":"2003","unstructured":"Haddad R, Colevas AD, Krane JF, et al: Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003, 39: 724-727. 10.1016\/S1368-8375(03)00097-6.","journal-title":"Oral Oncol"}],"container-title":["Head &amp; Neck Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1758-3284-3-31.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T16:55:50Z","timestamp":1630515350000},"score":1,"resource":{"primary":{"URL":"https:\/\/headandneckoncology.biomedcentral.com\/articles\/10.1186\/1758-3284-3-31"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,26]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["215"],"URL":"https:\/\/doi.org\/10.1186\/1758-3284-3-31","relation":{},"ISSN":["1758-3284"],"issn-type":[{"value":"1758-3284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,26]]},"assertion":[{"value":"28 June 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"31"}}